10.78

2.71% -0.30

After Hours: 10.60 -0.18 -1.67%

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $10.78, with a volume of 2.36M. It is down -2.71% in the last 24 hours and up +26.75% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$11.08

Open:

$11.03

24h Volume:

2.36M

Relative Volume:

0.86

Market Cap:

$2.37B

Revenue:

$52.04M

Net Income/Loss:

$-290.50M

P/E Ratio:

-7.4054

EPS:

-1.4557

Net Cash Flow:

$-240.94M

1W Performance:

+1.22%

1M Performance:

+26.75%

6M Performance:

+20.38%

1Y Performance:

-12.36%

1-Day Range:

$10.61

$11.05

1-Week Range:

$10.30

$11.74

52-Week Range:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

781-357-4000

Address

14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA

Employee

325

Twitter

@OCUTX

Next Earnings Date

2026-08-04

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	10.78	2.44B	52.04M	-290.50M	-240.94M	-1.4557
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-15-25	Initiated	Chardan Capital Markets	Buy
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Mar-11-25	Initiated	Needham	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

Aug 21, 2026

META_TITLE_QUOTE - Yahoo Finance

Aug 21, 2026

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance

Aug 21, 2026

Aug 20, 2026

Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn

Aug 19, 2026

Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat

Aug 19, 2026

Aug 18, 2026

Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28 - Moomoo

Aug 18, 2026

Why is Ocular Therapeutix stock rallying today? By Investing.com - Investing.com Canada

Aug 17, 2026

OCUL Looks 141.9% Overvalued on GF Value™ - GuruFocus

Aug 17, 2026

Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com - Investing.com South Africa

Aug 17, 2026

Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles - Investing.com

Aug 17, 2026

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - Stocktwits

Aug 17, 2026

Aug 15, 2026

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits

Aug 15, 2026

Aug 14, 2026

(OCUL) Volatility Zones as Tactical Triggers - Stock Traders Daily

Aug 14, 2026

Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued? - Sahm

Aug 14, 2026

OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210 - TradingKey

Aug 14, 2026

Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research - MarketBeat

Aug 14, 2026

Aug 13, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule - TradingView

Aug 13, 2026

Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option - Stock Titan

Aug 13, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 13, 2026

Aug 12, 2026

Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat

Aug 12, 2026

Aug 11, 2026

Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL - MarketBeat

Aug 11, 2026

Aug 10, 2026

The debate of durability in nAMD - Endpoints News

Aug 10, 2026